Connect with us

health

NAFDAC Begins Crackdown on Sachet Alcohol, Cites Risks to Children and Youth

Published

on

The National Agency for Food and Drug Administration and Control (NAFDAC) has commenced full enforcement of the ban on the production and sale of alcohol packaged in sachets and polyethylene terephthalate (PET) bottles below 200 millilitres, following a resolution of the Nigerian Senate.

adron lemon friday

The Director-General of NAFDAC, Prof. Mojisola Adeyeye, disclosed this on Wednesday in Lagos during a media briefing organised by the agency.

According to the News Agency of Nigeria (NAN), NAFDAC had on November 11, 2025, announced plans to begin enforcement of a total ban on the affected products by December 2025, in compliance with a directive issued by the Senate.

Adeyeye explained that the agency has now received a fresh formal authorisation from the upper legislative chamber to proceed, adding that enforcement actions have already commenced nationwide.

The Senate resolution of November 2025 followed a motion sponsored by Senator Ned Nwoko (Delta North), which was debated during plenary earlier this year. In moving the motion, Senator Nwoko raised concerns over the widespread availability of high-alcohol-content drinks packaged in sachets and small bottles, warning that their low cost and ease of concealment posed serious public health and social risks, particularly to minors and young adults.

The motion, which enjoyed broad bipartisan support, was debated by lawmakers who expressed alarm at rising cases of alcohol abuse among school-age children and youths. The Senate subsequently adopted the motion and resolved to direct NAFDAC to enforce existing regulations prohibiting the sale of alcoholic beverages in sachets and small-volume containers.

Speaking at the briefing, Adeyeye said the enforcement drive is aimed at safeguarding public health and protecting vulnerable groups, especially children, adolescents, and young adults, from the harmful effects of alcohol consumption.

“The proliferation of high-alcohol-content beverages in sachets and small containers has made such products easily accessible, affordable, and concealable,” she said.

She added: “We have already started the enforcement to ban alcohol production in sachets and bottles below 200ml after receiving the order from the Senate. NAFDAC is not against alcohol, but we are against its proliferation in high concentrations in sachets and small bottles, which makes it easy for children to access.”

Adeyeye noted that before her tenure, some sachet alcohol products contained between 50 and 90 per cent alcohol, describing the levels as dangerously high and detrimental to public health.

She said NAFDAC had previously directed manufacturers to reduce alcohol content to 30 per cent, but many resisted the directive, citing concerns over job losses and potential investment setbacks.

According to her, the matter was escalated to the Federal Ministry of Health, which subsequently granted manufacturers a five-year transition period from December 2018 to January 31, 2024, to restructure their operations and comply with regulatory standards.

Adeyeye reaffirmed the agency’s commitment to protecting public health, stressing that NAFDAC would continue to prioritise the safety of vulnerable populations through sustained regulatory enforcement.

48 / 100 SEO Score

News

NAFDAC Finds 11,400 Cartons of Banned Chemicals

Published

on

NAFDAC has uncovered nearly 11,400 cartons of banned agrochemicals, including Paraquat products, in Kano warehouses, raising fresh concerns about food safety and regulatory enforcement

(more…)

adron lemon friday

70 / 100 SEO Score
Continue Reading

health

FCCPC Moves Against Producers Over Poorly Fortified Oil, Salt

Published

on

FCCPC orders producers to comply with food fortification standards after a survey found inadequately fortified vegetable oil and salt in Nigerian markets

(more…)

adron lemon friday

68 / 100 SEO Score
Continue Reading

health

UK Tests Five-Day Breast Cancer Radiotherapy in Major Trial

Published

on

The UK is testing five-day breast cancer radiotherapy in a major trial that could reduce hospital visits and treatment costs for patients

The United Kingdom has launched a major clinical trial involving more than 1,000 participants to determine whether breast cancer radiotherapy can be shortened from three weeks to five days without compromising its effectiveness in preventing the disease from returning.

Also read: Grey CEO Urges Africa to Ditch Dollar for Trade

adron lemon friday

The government-funded FAST-Forward Boost trial, being conducted at 39 hospitals across the UK, will investigate whether a shorter course of radiotherapy combined with an additional targeted dose, known as a boost, can provide effective treatment for patients following breast cancer surgery.

The UK Department of Health and Social Care announced the development on Friday, October 30, describing the study as part of efforts to improve cancer treatment and make care more convenient for patients.

Led by the Institute of Cancer Research in London and funded by the National Institute for Health and Care Research, the study aims to recruit 4,830 participants by 2028.

Those enrolled will be followed up for five years, with results expected in 2033.

If the approach proves successful, it could reduce the number of hospital visits required by patients, potentially saving them 10 journeys compared with the existing three-week treatment schedule.

The department said the shorter schedule could also reduce transport expenses and the time patients spend away from work and family.

It could additionally ease pressure on the National Health Service by freeing up radiotherapy capacity for other patients.

Health and Social Care Secretary Yvette Cooper said the trial reflected the country’s efforts to use medical research to improve cancer care.

“This trial shows how the UK is using our world beating research capabilities to pursue huge improvements and transformations in cancer treatment for patients,” she said.

Why the radiotherapy trial matters

Radiotherapy uses carefully targeted radiation to destroy cancer cells or prevent them from growing.

For many people with breast cancer, it is recommended after surgery to reduce the risk of the disease returning in the treated area.

A treatment boost involves delivering an additional dose of radiation to the area considered to have a higher risk of recurrence, usually the site where the tumour was removed.

The FAST-Forward Boost trial is examining how this additional treatment can be incorporated into a shorter schedule.

Reducing treatment from three weeks to five days could make a considerable difference to patients who must travel regularly to hospitals.

The impact may be particularly significant for people living far from specialist cancer centres, those with limited transport options and patients balancing treatment with employment or family responsibilities.

However, the trial is designed to establish whether the shorter approach is effective and safe for the patients being studied. Its results will be important in determining whether the treatment schedule can become a wider option in clinical practice.

UK expands breast cancer screening efforts

The announcement comes as the British government intensifies efforts to improve breast cancer screening, encourage early diagnosis and strengthen support for patients.

The Department of Health and Social Care said screening uptake among women receiving their first invitation had risen to 63.6 per cent, its highest level in a decade.

Despite the improvement, around four in 10 women invited for their first screening appointment still do not attend.

The government is also working with the National Institute for Health and Care Research and NHS England on studies examining how artificial intelligence could support the analysis of mammograms.

The technology is being explored as a way to assist the assessment of breast screening images, although its role and effectiveness must be established through appropriate research and clinical evaluation.

In addition, the government has partnered with breast cancer charity Breast Cancer Now for three years to help women recognise symptoms, find reliable information and access support after treatment.

Together, the initiatives reflect a broader approach to breast cancer care, combining screening, research into treatment improvements and support for people living with the disease.

Also read: Grey CEO Urges Africa to Ditch Dollar for Trade

For now, the five-day radiotherapy approach remains under investigation. With final results not expected until 2033, the FAST-Forward Boost trial will need to establish whether reducing treatment time can deliver comparable cancer control while maintaining patient safety.

65 / 100 SEO Score
Continue Reading

Trending News